Study on Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy for Advanced Pancreatic Cancer

Inclusion Criteria

• Willing and able to follow the study plan, including treatments and scheduled visits.
• Diagnosed with advanced pancreatic cancer that cannot be surgically removed or has spread to other parts of the body.
  • Patients who had surgery before are not eligible unless the cancer has returned and can be treated with EUS-RFA.
  • If a metal stent is in place, it will be replaced with a plastic one during the procedure.
• Able to understand and agree to the study requirements.
• In good general health with an ECOG performance status of 0 to 2.
• Have at least one measurable cancer lesion based on imaging tests.
• Previous chemotherapy or radiation therapy is allowed if completed at least 6 months before joining the study.
• Meet specific blood test requirements for neutrophil and platelet counts, liver function, and kidney function.
• Any major surgery must have been completed at least 4 weeks before starting immunotherapy.

Exclusion Criteria

• No permanent address or phone number.
• Pregnant or breastfeeding, or not willing to use birth control during the study and for 90 days after the last dose.
• Incarcerated individuals.
• Unable to provide informed consent.
• Cancer that can be surgically removed or is borderline resectable.
• History of cancer spread to the brain or central nervous system.
• History of another primary cancer, unless it is not active or was treated successfully.
• Known low or absent enzyme activity affecting drug metabolism.
• Use of certain medications that affect liver enzymes.
• Significant or uncontrolled health conditions that could interfere with the study.
• History of HIV or active tuberculosis.
• Medical conditions that make pembrolizumab treatment risky.
• Psychiatric or substance abuse issues that could affect participation.
• Active autoimmune diseases or history of such diseases requiring treatment, except for certain conditions like stable hypothyroidism or controlled celiac disease.
• Recent use of immunosuppressive medications, with some exceptions for low-dose or specific types of steroids.